A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer

NCT07051486 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent or Metastatic Cervical Cancer

Interventions

DRUG: SHR-A1811 Injection

Sponsor

Jiangsu HengRui Medicine Co., Ltd.